Authors:
Gortzak, E
Azzarelli, A
Buesa, J
Bramwell, VHC
van Coevorden, F
van Geel, AN
Ezzat, A
Santoro, A
Oosterhuis, JW
van Glabbeke, M
Kirkpatrick, A
Verweij, J
Citation: E. Gortzak et al., A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma, EUR J CANC, 37(9), 2001, pp. 1096-1103
Citation: Mt. Gil et al., Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8subunit of the VP4 capsid protein, VIRAL IMMUN, 13(2), 2000, pp. 187-200
Authors:
Verweij, J
Lee, SM
Ruka, W
Buesa, J
Coleman, R
van Hoessel, R
Seynaeve, C
di Paola, ED
van Glabbeke, M
Tonelli, D
Judson, IR
Citation: J. Verweij et al., Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, J CL ONCOL, 18(10), 2000, pp. 2081-2086
Authors:
Buesa, J
de Souza, CO
Asensi, M
Martinez, C
Prat, J
Gil, MT
Citation: J. Buesa et al., VP7 and VP4 genotypes among rotavirus strains recovered from children withgastroenteritis over a 3-year period in Valencia, Spain, EUR J EPID, 16(6), 2000, pp. 501-506
Authors:
Van Glabbeke, M
van Oosterom, AT
Oosterhuis, JW
Mouridsen, H
Crowther, D
Somers, R
Verweij, J
Santoro, A
Buesa, J
Tursz, T
Citation: M. Van Glabbeke et al., Prognostic factors for the outcome of chemotherapy in advanced soft tissuesarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatmentof Cancer Soft Tissue and Bone Sarcoma Group Study, J CL ONCOL, 17(1), 1999, pp. 150-157
Authors:
Buesa, J
Raga, JV
Colomina, J
de Souza, CO
Munoz, C
Gil, MT
Citation: J. Buesa et al., Rotavirus-specific cytotoxic T lymphocytes recognize overlapping epitopes in the amino-terminal region of the VP7 glycoprotein, VIROLOGY, 257(2), 1999, pp. 424-437
Authors:
Nielsen, OS
Dombernowsky, P
Mouridsen, H
Crowther, D
Verweij, J
Buesa, J
Steward, W
Daugaard, S
van Glabbeke, M
Kirkpatrick, A
Tursz, T
Citation: Os. Nielsen et al., High-dose epirubicin is not an alternative to standard-dose doxorubicin inthe treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group, BR J CANC, 78(12), 1998, pp. 1634-1639